On March 28, Shanghai Haohai Biological Technology Co.Ltd(688366) issued the 2021 report. With the effective control of covid-19 epidemic in China, the impact of covid-19 epidemic on the group’s business activities has gradually weakened, and all businesses have achieved significant growth, showing a trend of continuous recovery, stability and improvement.
In 2021, Shanghai Haohai Biological Technology Co.Ltd(688366) achieved an operating revenue of 1.767 billion yuan, a year-on-year increase of 32.61%; The net profit attributable to shareholders of listed companies and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses were divided into 352 million yuan and 328 million yuan, an increase of 53.10% and 58.88% respectively over the previous year. The company plans to distribute cash dividends of RMB 7.00 (including tax) to all shareholders for every 10 shares, with a total of RMB 123 million (including tax), accounting for 34.94% of the net profit attributable to shareholders of Listed Companies in the consolidated statements of the company in 2021.
In the business product series, the business income of ophthalmic products is 674 million yuan, accounting for the largest proportion of revenue, accounting for 38.34%; The business income of medical beauty and wound care products grew the fastest, with a year-on-year increase of 91.49%.
During the reporting period, Shanghai Haohai Biological Technology Co.Ltd(688366) continued to increase R & D investment, focusing on expanding the innovative product lines of Ophthalmology and medical aesthetics. The R & D expenses incurred in the current period were 168 million yuan, an increase of 32.51% year-on-year. The proportion of R & D expenses in operating revenue reached 9.48%.
In 2022, Shanghai Haohai Biological Technology Co.Ltd(688366) will continue to further promote the integration of internal resources, and further strengthen the integration of acquired enterprises in various links such as R & D, production, sales and services, so as to maximize synergy, improve operation efficiency, develop innovative technology and expand market space, so that the acquired enterprises can quickly integrate into the group’s management system, continue to give full play to their collaborative advantages and enhance their core competitiveness.
It is understood that Shanghai Haohai Biological Technology Co.Ltd(688366) will continue to effectively use its own funds, deepen the layout of myopia prevention and control and refractive correction on the basis of the existing layout of the whole ophthalmic industry chain, and continue to pay attention to more ophthalmic treatment fields such as ocular surface and fundus. In addition, the group will also explore the rapidly developing treatment fields such as medical aesthetics, orthopedics and surgery, actively look for advanced technologies and excellent products, choose the opportunity to adopt technology introduction or investment cooperation to thicken the product reserve and achieve long-term sustainable growth.
According to public data, Shanghai Haohai Biological Technology Co.Ltd(688366) is a leading enterprise in the field of biomedical materials in China, and has achieved industry-leading advantages in four business segments: Ophthalmology, medical beauty and wound care, orthopedics, anti adhesion and hemostasis.
